Immunic - About the company
Immunic is a public company based in New York City (United States), founded in 2003. It operates as a Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Immunic has raised an undisclosed amount in funding. The company has 395 active competitors, including 147 funded and 108 that have exited. Its top competitors include companies like ADMA Biologics, BioNTech and Abcellera Biologics.
Company Details
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
- Website
- imux.com
- Social
- Email ID
- *****@imux.com
- Phone Number
- +1 **********
- Registered Address
- New York, New York
Key Metrics
Founded Year
2003
Location
New York City, United States
Stage
Public
Latest Funding Round
Investors
Ranked
46th among 395 active competitors
Employee Count
87 as on Mar 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Immunic
Immunic is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
IMMUNIC, INC. CIN: 562358443 , United States, Active | Dec 31, 1999 | - | 7 (As on Dec 31, 2024) | - |
Immunic, Inc CIN: 56-2358443 , United States, Active | Dec 31, 2002 | - | 77 (As on Dec 31, 2023) | - |
IMMUNIC, INC. CIN: 5660722 , United States, Active | Nov 22, 2019 | - | - | - |
Immunic Ag CIN: HRB223333 , Germany, Active | Jan 24, 2016 | - | 28 (As on Mar 31, 2021) |
Immunic's IPO details
Immunic got listed on Apr 17, 2014.
Click here to take a look at Immunic's IPO in detail
Sign up to download Immunic's company profile
Immunic's funding and investors
Immunic has raised funding over 4 rounds. Its first funding round was on Sep 27, 2016. Its latest funding round was a Post IPO round on Feb 13, 2026 for $*****. 11 investors participated in its latest round. Immunic has 23 institutional investors.
Here is the list of recent funding rounds of Immunic:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 13, 2026 | 1411494 | Post IPO | 8033826 | 2222913 | 2719692 | 6299062 |
Jan 04, 2024 | 7613455 | Post IPO | 4269193 | 4490216 | 7808672 | |
Oct 10, 2022 | 2658998 | Post IPO | 9321820 | 5061304 | 7508199 | 8519145 |
Access funding benchmarks and valuations. Sign up today!View details of Immunic's funding rounds and investors
Immunic's founders and board of directors
Founder? Claim ProfileImmunic's employee count trend
Immunic has 87 employees as of Mar 26. Here is Immunic's employee count trend over the years:
Uncover Immunic's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immunic's Competitors and alternates
Top competitors of Immunic include ADMA Biologics, BioNTech and Abcellera Biologics. Here is the list of Top 10 competitors of Immunic, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 71/100 | |
2nd | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
3rd |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 69/100 | |
4th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
5th | Apellis Pharmaceuticals 2008, Crestwood (United States), Public | Developer of therapeutics for the treatment of rare diseases | $213M | 68/100 | |
6th | PureTech Health 2001, Boston (United States), Public | Developer of immunotherapeutics for multiple diseases | $107M | 67/100 | |
7th |  Cabaletta Bio 2017, Radnor (United States), Public | Developer of CAAR T cells for B cell-mediated autoimmune diseases | $88.3M | 67/100 | |
8th |  Vera Therapeutics 2016, San Francisco (United States), Public | Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases | $197M | 66/100 | |
9th |  Generate Biomedicines 2018, Somerville (United States), Public | Developer of a platform for generating novel protein-based therapeutic modalities | $693M | 66/100 | |
10th |  Astria 2008, Boston (United States), Acquired | Developer of therapeutics for rare diseases | $117M | 65/100 | |
46th |  Immunic 2003, New York City (United States), Public | Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases | - | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immunic's competitors? Click here to see the top ones
Immunic's Investments and acquisitions
Immunic has made no investments or acquisitions yet.
Reports related to Immunic
Here is the latest report on Immunic's sector:
News related to Immunic
Filter this listMedia has covered Immunic for a total of 16 events in the last 1 year, 5 of them have been about company updates and 2 about people movement.
•
•
•
•
•
Dentons Advises Immunic, Inc. on Private Placement and Royalty TransactionsLegal Desire•Mar 06, 2026•Immunic, Dentons
•
•
Immunic Announces Oversubscribed Private Placement of up to USD 400 MillionPR Newswire•Feb 13, 2026•Immunic, BVF Partners, Immunic, B. Riley Securities
•
Immunic Presents Phase 2 Trial Data for Vidofludimus Calcium at ACTRIMS Forum 2026WebDisclosure•Feb 04, 2026•Immunic
•
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR Newswire•Nov 13, 2025•Immunic
•
Immunic Receives Notice of Allowance for US Patent Protecting Vidofludimus CalciumPR Newswire•Sep 09, 2025•Immunic
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immunic
Explore our recently published companies
- Kaizen - Unfunded company
- Ford Country - Henderson based, 1996 founded, Unfunded company
- A2Z Creations - Panipat based, 2015 founded, Unfunded company
- IRG Commercial - Altamonte Springs based, 1989 founded, Unfunded company
- GMR Quality Stone Products - Sterling Heights based, 2002 founded, Unfunded company
- Socalweb - Los Angeles based, 2004 founded, Unfunded company
